Form 4: Acadia Director Poole Granted Stock Options, RSUs

Acadia Pharmaceuticals Director Jonathan Poole received new stock options and restricted stock units as part of his compensation.

Summary

• Jonathan Poole, a Director at ACADIA PHARMACEUTICALS INC., reported changes in his beneficial ownership.
• He was granted 7,482 Director Stock Options with an exercise price of $22.5, vesting in equal annual installments over three years following the grant date of March 3, 2026.
• An additional 3,565 Director Stock Options were granted at an exercise price of $22.5, vesting quarterly over one year following the grant date of March 3, 2026, or until the next annual meeting of stockholders.
• Poole also received 4,218 Restricted Stock Units (RSUs) vesting in equal annual installments over three years following the grant date of March 3, 2026.
• A further 2,010 Restricted Stock Units were granted, vesting in full on the earlier of one year following the grant date of March 3, 2026, or the next annual meeting of stockholders.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard director compensation practices that align interests with shareholders, without indicating any significant operational or financial changes.

Positives

• The grants align the director's interests with long-term shareholder value through equity incentives.
• The vesting schedules encourage continued service and performance from the director.

Negatives

• No direct negatives are apparent from a routine equity grant filing.

Risks

• No specific risks are mentioned in this Form 4 filing, which primarily reports compensation.

Future Outlook

This Form 4 primarily reports past transactions and does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that equity grants to directors and executives are a standard practice in the pharmaceutical and biotechnology industry, aiming to incentivize long-term performance and align management interests with shareholder value. These grants are typical components of a competitive compensation package designed to attract and retain top talent in a highly specialized sector.

Comparison to Industry Standards

• The use of both stock options and restricted stock units (RSUs) is a common practice in executive and director compensation across the biotech and pharmaceutical sectors, similar to companies like Biogen Inc. or Gilead Sciences, Inc.
• Vesting schedules, such as three-year annual installments for some grants and one-year or next annual meeting vesting for others, are standard mechanisms to promote retention and long-term commitment, comparable to practices seen at peer companies.
• The exercise price of $22.5 for stock options is set at the market price on the grant date, which is a standard, non-discounted approach for incentive options.

Corporate Governance

Related Party Transactions

• The grants of stock options and restricted stock units to Director Jonathan Poole constitute a related party transaction, which is a standard, disclosed form of executive compensation.

Stakeholder Impact

• Shareholders: The grants align the director's incentives with shareholder value creation, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is noted, but it reflects the company's compensation philosophy for leadership.

Next Steps

• The stock options and restricted stock units will vest according to their respective schedules over the next one to three years.
• The next annual meeting of stockholders will be a vesting trigger for some grants.

Key Dates

Recommendation

This Form 4 filing reports routine equity compensation for a director and does not contain information that would significantly alter the fundamental investment thesis for ACADIA PHARMACEUTICALS INC. It is a standard disclosure of insider transactions, not indicative of a major operational or strategic shift. Therefore, a "hold" recommendation is appropriate as it provides no new material information to change an existing position.

Keywords

ACADIA PHARMACEUTICALS, ACAD, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation, Jonathan Poole